Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPTSY Biophytis	$2.00 +10.8%	$1.61	$1.33 ▼ $7.48	$702K	0.85	1,678 shs	335 shs
CAPS Capstone Therapeutics	$1.09 -4.4%	$1.56	$1.03 ▼ $16.18	$180K	-0.8	132,275 shs	90,107 shs
HEPA Hepion Pharmaceuticals	$0.06 -12.0%	$0.06	$0.03 ▼ $0.08	$652K	1.52	87,478 shs	30,072 shs
PBLA Panbela Therapeutics	$0.16	$0.19	$0.05 ▼ $0.47	$767K	1.33	16,444 shs	592 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPTSY Biophytis	0.00%	+10.80%	+10.80%	-3.85%	-67.16%
CAPS Capstone Therapeutics	-8.06%	-8.06%	-29.63%	-42.13%	+113,999,900.00%
HEPA Hepion Pharmaceuticals	+2.86%	+7.46%	+53.19%	-20.00%	-99.80%
PBLA Panbela Therapeutics	0.00%	0.00%	-1.31%	-35.89%	-57.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BPTSY Biophytis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CAPS Capstone Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HEPA Hepion Pharmaceuticals	1.0734 of 5 stars	0.0	5.0	0.0	0.0	2.5	0.0	0.6
PBLA Panbela Therapeutics	0.9523 of 5 stars	0.0	5.0	0.0	0.0	3.3	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPTSY Biophytis	N/A	N/A	N/A
CAPS Capstone Therapeutics	N/A	N/A	N/A
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A
PBLA Panbela Therapeutics	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPTSY Biophytis	N/A	N/A	N/A	N/A	($16.18) per share	N/A
CAPS Capstone Therapeutics	$44.88M	0.00	N/A	N/A	$166.51 per share	0.01
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A	N/A	$1.29 per share	N/A
PBLA Panbela Therapeutics	N/A	N/A	N/A	N/A	($18.37) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPTSY Biophytis	-$18.43M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CAPS Capstone Therapeutics	-$2.56M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
HEPA Hepion Pharmaceuticals	-$48.93M	-$219.00	N/A	∞	N/A	N/A	-812.56%	-207.31%	N/A
PBLA Panbela Therapeutics	-$25.26M	-$71.13	N/A	∞	N/A	N/A	N/A	-302.61%	N/A

Latest CAPS, PBLA, HEPA, and BPTSY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/15/2025	Q2 2025	CAPS Capstone Therapeutics	N/A	-$0.13	N/A	-$0.13	N/A	$12.85 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPTSY Biophytis	N/A	N/A	N/A	N/A	N/A
CAPS Capstone Therapeutics	N/A	N/A	N/A	N/A	N/A
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PBLA Panbela Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPTSY Biophytis	N/A	0.41	N/A
CAPS Capstone Therapeutics	0.22	0.97	0.47
HEPA Hepion Pharmaceuticals	N/A	1.30	1.30
PBLA Panbela Therapeutics	N/A	0.26	0.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPTSY Biophytis	0.05%
CAPS Capstone Therapeutics	2.55%
HEPA Hepion Pharmaceuticals	17.24%
PBLA Panbela Therapeutics	4.37%

Insider Ownership

Company	Insider Ownership
BPTSY Biophytis	3.70%
CAPS Capstone Therapeutics	42.80%
HEPA Hepion Pharmaceuticals	0.06%
PBLA Panbela Therapeutics	0.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPTSY Biophytis	30	351,000	338,000	N/A
CAPS Capstone Therapeutics	38	160,000	90,000	N/A
HEPA Hepion Pharmaceuticals	20	11.44 million	6.63 million	No Data
PBLA Panbela Therapeutics	6	4.86 million	4.86 million	Not Optionable

CAPS, PBLA, HEPA, and BPTSY Headlines

Recent News About These Companies

Panbela Therapeutics Announces Q3 2024 Financial Results

November 16, 2024 | markets.businessinsider.com

Panbela Therapeutics, Inc.: Panbela Provides Business Update and Reports Q3 2024 Financial Results

November 15, 2024 | finanznachrichten.de

Panbela Therapeutics Inc (PBLA) Q3 2024 Earnings Call Highlights: Strategic Loan and Clinical ...

November 15, 2024 | finance.yahoo.com

Panbela Therapeutics, Inc. (PBLA) Q3 2024 Earnings Call Transcript

November 14, 2024 | seekingalpha.com

Panbela Provides Business Update and Reports Q3 2024 Financial Results

November 14, 2024 | globenewswire.com

Panbela Therapeutics (OTC:PBLA) Stock, Insider Trading Activity

October 6, 2024 | benzinga.com

Horace Mann Educators (NYSE:HMN) Stock Quotes, Forecast and News Summary

October 5, 2024 | benzinga.com

Panbela Therapeutics (OTC:PBLA) Stock, Short Interest Report

October 5, 2024 | benzinga.com

Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q2 2024 Earnings Call Transcript

August 15, 2024 | insidermonkey.com

Panbela Therapeutics, Inc. (PBLA) Q2 2024 Earnings Call Transcript

August 14, 2024 | seekingalpha.com

Panbela Provides Business Update and Reports Q2 2024 Financial Results

August 13, 2024 | globenewswire.com

Is Panbela Therapeutics Inc (PBLA) Stock a Good Investment?

August 3, 2024 | aaii.comA

Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024

July 30, 2024 | globenewswire.com

Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification

June 24, 2024 | globenewswire.com

Panbela Therapeutics Inc. (PBLA) Insider Activity

May 25, 2024 | nasdaq.com

HC Wainwright & Co. Downgrades Panbela Therapeutics (PBLA)

May 17, 2024 | msn.com

Q1 2024 Panbela Therapeutics Inc Earnings Call

May 16, 2024 | uk.finance.yahoo.com

Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q1 2024 Earnings Call Transcript

May 16, 2024 | msn.com

Panbela Therapeutics Inc (PBLA) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...

May 16, 2024 | finance.yahoo.com

Panbela Provides Business Update and Reports Q1 2024 Financial Results

May 15, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CAPS, PBLA, HEPA, and BPTSY Company Descriptions

Biophytis NASDAQ:BPTSY

$2.00 +0.20 (+10.80%)

As of 08/15/2025 02:08 PM Eastern

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Capstone Therapeutics NASDAQ:CAPS

$1.09 -0.05 (-4.39%)

As of 04:00 PM Eastern

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Hepion Pharmaceuticals NASDAQ:HEPA

$0.06 -0.01 (-12.04%)

As of 02:36 PM Eastern

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Panbela Therapeutics NASDAQ:PBLA

$0.16 0.00 (0.00%)

As of 08/18/2025 03:30 PM Eastern

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time